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doi:10.1016/j.ejvs.2011.05.023Abstract Objective: Strokes, a major cause of disability, are often caused by embolism from
unstable carotid plaques. The aim of this study was to validate a biobank of human carotid
endarterectomies as a platform for further exploration of pathways for plaque instability.
For this purpose, we investigated the relationship between clinical parameters of plaque insta-
bility and expression of genes previously shown to be associated with either plaque instability
or healing processes in the vessel wall.
Methods: A database of clinical information and gene-expression microarray data from 106
carotid endarterectomies were used.
Results: Expression of matrix metalloproteinase (MMP)-9 and MMP-7 was 100-fold higher in pla-
ques than in normal artery. In general, genes associated with inflammation (such as RANKL and
CD68) were overexpressed in symptomatic compared with asymptomatic plaques. Plaques ob-
tained from patients undergoing surgery within 2 weeks after an embolic event showed up-
regulation of genes involved in healing reactions in the vessel wall (including elastin and
collagen). Statin treatment, as well as echodense lesions, were associated with a more stable
phenotype.
Conclusion: Here, we demonstrate that gene-expression profiles reflect clinical parameters.
Our results suggest that microarray technology and clinical variables can be used for the future
identification of central molecular pathways in plaque instability.
ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.623 844 75; fax: þ46 8 339 309.
i.se (A. Razuvaev).
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Gene Expression in Carotid Atherosclerosis 723Stroke as a result of plaque rupture and embolisation from oligonucleotide arrays, the total expression pattern of
unstable atherosclerotic lesions in the carotid bifurcation is
an important cause of death and disability in the Western
world. Patients with high-grade internal-carotid-artery
(ICA) stenosis are treated with stroke-preventive surgical
intervention, according to clinical guidelines.1 Even though
experimental studies and examinations of human carotid
plaques have provided insights into the cellular and
molecular mechanisms involved in plaque instability,
further exploration is required to improve the selection of
patients with vulnerable lesions for intervention, apart
from the degree of carotid stenosis.
The vulnerability of an atherosclerotic lesion has largely
been attributed to inflammation.2,3 The activity of pro-
inflammatory T-cells and macrophages, cytokine release,
secretion ofmatrixmetalloproteinases (MMPs), thinning of the
fibrous cap due to impaired collagen-fibre formation, colla-
genolysis and apoptosis of smooth muscle cells (SMCs) may,
together with haemodynamic forces, cause fibrous-cap
rupture, exposure of tissue factor and thrombosis.2,3 In
a similar fashion, lesions are stabilised when SMCs proliferate
and deposit collagen, such as in healing of lesions after silent
plaque rupture, and when inflammatory processes are
restricted.3,4 Although information on healing processes in
human atherosclerosis is limited, there is abundant experi-
mental data in the literatureonmechanisms involved in vessel-
wall repair and healing processes, such as intimal hyperplasia.
A number of clinical parameters influence the risk of
stroke in patients with carotid stenosis. Patients with
asymptomatic carotid stenosis have an annual stroke risk of
approximately 2%, whereas symptomatic patients with
either transitory ischaemic attack (TIA) or minor stroke (MS)
as a sign of carotid plaque instability and cerebral emboli-
sation suffer a risk of approximately 5% within the first 2
weeks after the index event.5,6 Stroke risk is also associated
with clinical symptoms, and patients with either TIA or MS
have a higher risk than patients with ocular symptoms
(amaurosis fugax, AF).6 The risk of recurrent embolisation is
also most pronounced within the first 2 weeks after the
index event, and plaque morphology changes with time
after stroke and TIA.5,7 Possibly, these clinical features
represent plaque rupture followed by a healing response
involving repair mechanisms with SMC proliferation and
synthesis of extracellular matrix components.8 Various
imaging methods have been assessed to diagnose unstable
and stroke-prone carotid lesions in addition to determina-
tion of the degree of stenosis. Duplex ultrasound is routinely
used to diagnose carotid stenosis and to calculate the
degree of stenosis. The method may also determine plaque
morphology and the degree of echolucency, which has been
proposed to predict risk of stroke.9 Medical therapy has
a great impact on the natural course of carotid disease, and
treatment with hydroxymethylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors (statins) significantly reduce
stroke risk most likely by reducing plaque inflammation.3,10
Our understanding of molecular risk factors for athero-
sclerosis is almost exclusively based on hypothesis-driven
research. However, modern molecular medicine has
permitted a hypothesis-independent exploration to identify
molecular mediators expressed in the pathologic tissue. By
isolating RNA from lesions, reverse transcribing it to comple-
mentary DNA (cDNA) and hybridising to ‘global’a pathological tissue can be deduced. Seeking new informa-
tion on healing processes in human atherosclerosis, we have
created a biobank of carotid endarterectomies. In the bio-
bank, we collected detailed information about the patients’
history includingrisk factors,medications, symptomsand time
of surgery, in addition to results of global gene-expression
analysis from plaques retrieved from carotid surgery. The
Biobank of Karolinska Endarterectomies (BiKE), which
contains more than 400 atherosclerotic lesions, 100 of which
havebeen subjected toglobal-expressionarray, hasbeenused
in a number of studies where the pattern of differentially
expressedgeneshavebeen identified in relation to thedisease
history and the effect of medical treatment.11,12
The major aim of the present article was to validate the
biobank as a platform for exploring new pathways involved
in plaque instability. We chose a biased approach and
limited the genes studied to 317 candidates already known
to be associated either with plaque instability or healing
processes in the vessel wall and correlated the gene-
expression analysis to clinical parameters.
Methods
For more information, please see Supplementary Materials.
The material is a part of the BiKE project. Atheroscle-
rotic carotid plaques were retrieved from surgery of 106
patients after informed consent. For controls, iliac arteries
were obtained at organ transplantation from healthy
donors.
Clinical parameters
The clinical variables used for the study included: presence
and type of symptoms, time between the last symptom and
surgery, statin treatment and duplex ultrasound assessment
of carotid plaque echodensity. Symptoms of plaque insta-
bility were defined as TIA, MS and/or AF. A few patients had
a combination of AF with either TIA or MS (Table 1). The
time between the last date of qualifying symptoms and
date of the endarterectomy procedure was calculated in
days, thus: within the first 14 days, between 15 and 30
days, between 31 and 90 days and more than 90 days. The
majority of the patients (81%) were treated with statins.
Plaque echodensity was assessed during the preoperative
routine duplex examination by an ultrasound specialist and
recorded in a qualitative way as either echolucent, echo-
dense or not specified.
The study was approved by the Ethical Committee of
Northern Stockholm and was in agreement with institu-
tional guidelines and the principles set forth in the Decla-
ration of Helsinki.
Complete characteristics of the risk factors, comorbidity
and medication are presented in Supplement 1.
Selection of genes
Genes representing proteins associated with either plaque
instability or healing processes in the vessel wall were
selected through a PubMed reference-based biased
approach. We started with review articles focussing on the
Table 1 Patient baseline characteristics and distribution.
TIA e transitory ischaemic attack, AF e amaurosis fugax.
For complete characteristics of the risk factors, comorbidity
and medication please see Tables at the end of the
supplement I.
Number of patients 106
Age, years 70 (46e85)
Gender
Male 85
Female 21
Symptoms
Asymptomatic 35
Symptomatic 71
Stroke 30
TIA 26
AF 15
Time from symptom, days
<15 15
15 to 30 19
30 to 90 21
>90 12
Unknown 4
Statin therapy
Yes 84
No 20
Unknown 2
Echodensity
Echodense 15
Echolucent 21
Undefined 70
Table 2 Gene classification.
Green SMC activation and proliferation
Anti-inflammatory
Anti-apoptotic
MMP inhibition
SMC markers
Light-green ECM components and production
Cytoskeletal
Cellematrix interactions
Endothelial cell markers
Orange Cell adhesion
Lipid metabolism
Coagulation
Angiogenesis
Red Pro-inflammatory
Pro-apoptitic
Anti-proliferative
ECM degradation
Inflammatory cell markers
724 A. Razuvaev et al.stability of atherosclerotic plaques. Additional information
was obtained from studies where gene expression was
assessed in human lesions. This procedure yielded a list of
proteins, which was complemented with extracellular
matrix components and vascular and inflammatory cell
markers. A number of proteins had family members with
similar functions; genes coding these molecules were also
included in the analysis. The final register included
messenger RNAs (mRNAs) encoding 317 proteins. Each
protein was assigned to a function code by using literature
data, together with the Gene Ontology Function Terms
database. Out of three function codes, the most relevant
one was used for sorting, and all genes were divided into
four main functional groups, according to the role they may
play in atherosclerotic plaques. To aid data presentation,
the four groups were given colour codes to indicate general
function (Table 2). The detailed list of the genes with the
functional classification and references is presented in
Supplement 2.
Results
Gene expression in carotid plaques and normal
arteries
Comparison of the relativemRNAexpressionof the chosen 317
genesbetweencarotidplaquesandnormalvesselwall showed
several significant changes. In general, overexpression of the
investigated genes was more common and more significant.Notably, themRNA levels for MMP-9 and MMP-7 were found to
be more than 100-fold higher (Supplement 3, Table 3). Genes
that showed lower expression in plaques included phospholi-
pase A2G2A, Filamin-C and smooth muscle-actin a1, which
were all strongly decreased. As illustrated by the volcano plot
(Supplement 3, Fig. 3), genes with increased expression in
plaques were related to inflammatory processes in the vessel
wall, whilemost of the geneswith decreased expressionwere
related to extracellularmatrix components aswell asmarkers
of SMCs.
Gene-expression profiles of symptomatic and
asymptomatic patients
In carotid plaques from symptomatic patients, 11 genes
were significantly down-regulated in comparison with pla-
ques from asymptomatic patients (myocardin, collagen IV
a6, elastin, tropomyosin b, platelet-derived growth factor-
D (PDGF-D), reduced nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase 4, PDZ and LIM domain 7,
osteoglycin, interferon a10, transgelin and carbohydrate
sulphotransferase 12), while mRNA levels of 19 genes were
increased (among those: insulin-like growth factor (IGF)-
binding protein-1 (IGFBP1), ADAM 8 (a disintegrin and
metalloprotease domain), MMP-3, vascular endothelial
growth factor-A (VEGF-A), MMP-9, CD68 and thromboxane A
synthase 1). When genes were classified according to the
ontology described above (Supplement 3, Table 4), those
related to inflammatory and proteolytic activity showed
higher expression in lesions from symptomatic patients,
whereas SMC markers displayed reduced expression levels.
This pattern is illustrated in the volcano plot (Fig. 1) with
the comparison between expression profiles of symptom-
atic and asymptomatic lesions. The genes in the upper-left-
and the upper-right region have a small P value with a large
fold change. This type of a scatter plot is used to simulta-
neously depict the P value and the fold change for gene
selection in microarray data. It may be viewed as
a summary of significance and average magnitude of change
over a large number of genes.
Figure 1 Genes differentially expressed in carotid plaques obtained from symptomatic patients in comparison with plaques from
asymptomatic patients. The volcano plot illustrates simultaneously the P value and the fold change for the 317 genes. The x-axis is
the log2 fold change and the y-axis is P value in log2 scale. Genes highly expressed in symptomatic lesions are located to the left,
while genes with higher expression in asymptomatic ones landing to the right. The dash line shows the P value level of 0.05. Genes
landing above the line have a lower P value.
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Gene-expression profiles in patients with TIA or MS were
compared with patients with ocular symptoms (AF). Among
the 317 genes, only expression of phosphatidyl inositol-3 (PI3)
kinase and tumour necrosis factor receptor (TNFR) super-
family member 11b was significantly lower in plaques from
patients with MS and TIA, whereas nine genes were signifi-
cantly up-regulated (among those: apolipoprotein E, integrin
aM and interferons a1 and a4). Genes differentially expressed
inplaques frompatientswitheither strokeorTIAas compared
with subjectswithAFare shown in the Supplementary Table 5
and the volcano plot (Fig. 5, Supplement 3).Gene expression in relation to time between
symptom and surgery
The time between the last qualifying symptom of plaque
instability (MS, TIA or AF) and surgery influenced gene-
expression profiles in plaques. Comparison of mRNA-
expression levels between the first (within 15 days) and the
third group (31e90 days) revealed a significantly increased
expression of five genes (TNF a, interferons g and a1,
vitronectin and tubulin a3C; Fig. 2) in lesions from patients
with a longer symptom-free interval before surgery.The expression profiles in relation to time from the
symptom are also demonstrated in the volcano plot (Fig. 6,
Supplement 3) and Supplementary Table 6, where genes are
sorted according to differences in gene-expression levels in
plaques from patients with recent symptoms (within 15
days) and in plaques from patients with a longer symptom-
free interval before surgery (31e90 days). Interestingly,
most SMC-marker genes, together with genes for elastin
and collagen proteins, were among those highly expressed
in plaques from patients with recent symptoms. By
contrast, genes with increased expression in specimens
acquired from patients undergoing surgery more than 1
month after the last symptom were attributed to inflam-
matory processes and matrix degradation (PLA2G7 (phos-
pholipase A2, group VII (platelet-activating factor
acetylhydrolase, plasma)), MMP-12 and TNF). This finding
was supported by the observation that also expression of
inflammatory-cell-marker genes (CD68 and CD163) was
increasing over time.
Gene expression in relation to statin treatment
Comparison of gene expression in lesions from patients with
or without statin treatment showed marked differences.
There were slightly more genes with significantly increased
expression in patients on this medication (25 genes) than
Figure 2 mRNA-expression levels (y-axis, arbitrary units) for selected genes in plaques obtained from symptomatic patients in
relationship to time (x-axis, days) between symptom and surgery. Data is presented as Box and whiskers plots (10th percentile e
lowest point on whisker, 90th percentile-highest point on vertical whisker). P value below 0.05 indicated with *, below 0.005 e **.
726 A. Razuvaev et al.there were with decreased expression levels (17 genes).
Among those with increased expression were cyclin D,
plasminogen activator inhibitor-1, tissue plasminogen
activator, Kruppel-like factor 4, tissue factor and tubulin g.
Expression of the genes specific for SMCs as well as
inflammatory cell markers seemed to be unaffected bystatin treatment (Supplementary Table 7 and Fig. 7,
Supplement 3). Notably, expression of geranylgeranylpyr-
ophosphate synthase was found to be increased in plaques
from statin-treated patients, possibly as a result of
a compensatory response to inhibition of HMG-CoA
reductase.
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Plaque echodensity was assessed as part of the preopera-
tive duplex ultrasound routine examination in 36 patients
and was used in this study as a marker of plaque stability.
About 70% of the echolucent plaques were symptomatic,
while 80% of echodense lesions caused symptoms. Relative
mRNA levels of interleukin (IL)-10, ADAM 30 and tryptase g
were significantly higher in echolucent plaques when
compared with echodense ones, whereas mRNA levels for
eight proteins (including IGF1R, collagen type III a1 and
fibromodulin) were lower. In general, analysis of mRNA
levels showed a more inflammatory and unstable profile in
echolucent lesions compared with echodense ones
(Supplementary Table 8, Fig. 8, Supplement 3).
Identification of gene-expression patterns in
unstable carotid plaques
When comparisons between the influences of various clin-
ical parameters on gene-expression patterns were per-
formed, we observed that expression of several genes was
affected in a similar manner. Six different comparisons
were made between clinical variables and gene expression
in carotid plaques (plaques vs. control artery, symptomatic
vs. asymptomatic lesions, TIA and MS vs. AF, time between
symptoms and surgery, statin vs. no statin treatment and
echolucent vs. echodense lesions). In five of the compari-
sons, synergetic changes were seen for angiotensin II
receptor, fibroblast growth factor 2 (FGF2) and SMC-marker
genes: myosin heavy chain and myocardin were up-Table 3 Summary of genes commonly dependent on clinical va
Tables 3e8 (*p  0,05).regulated in plaque stabilisation, together with tropomy-
osin b, which appeared with increased expression in four
comparisons. By contrast, MMP-7, as related to plaque
instability, was increased in four comparisons followed by
MMP-9, CD68 and CD163, which appeared in three
comparisons. Other genes differently regulated in relation
to the described variables are presented in Table 3.
Discussion
Here, we used a biobank resource (BiKE) consisting of
a database of clinical parameters coupled to mRNA-
expression microarrays from 106 carotid plaques obtained
from patients undergoing carotid endarterectomy) for
asymptomatic and symptomatic carotid stenosis. Clinical
variables reflecting lesion instability were shown to corre-
late to expression profiles of genes previously proposed to
be involved in either destabilising or stabilising processes in
the vessel wall.
As expected, we found dramatic differences in gene-
expression levels between normal artery wall and lesions.
MMP-9 and -12 were overexpressed in lesions followed by
other proteases and inflammatory mediators, in agreement
with previous reports.13 Control samples had a higher
expression of SMC-specific genes, while levels of the
macrophage marker CD68 were lower. This confirms the
difference in cellular content between a normal arterial
media and a diseased and inflammatory intima. Compari-
sons between asymptomatic and symptomatic plaques
demonstrated discrete differences in mRNA levels with
a trend towards overexpression of genes related toriables used in the study based on the analysis presented in
728 A. Razuvaev et al.inflammation, such as MMPs, in symptomatic and unstable
lesions, whereas asymptomatic plaques had higher levels of
mRNA coding for extracellular-matrix proteins and SMC
markers. This is in accordance with previous findings
showing higher MMP-9 expression in symptomatic lesions14
and increased matrix degradation in vulnerable plaques.13
Symptomatic plaques displayed higher levels of mRNA for
angiogenic factors and overexpression of CD163.15
Patients with either MS or TIA carry a higher stroke risk
than subjects with retinal events.6 Analysis of carotid
endarterectomy samples has revealed structural similari-
ties between lesions from asymptomatic patients and
subjects with AF, and it has been suggested that AF may be
caused by microembolisation from discrete erosions rather
than complete atheroma rupture with thrombosis.16 AF has
also been suggested to be caused by either lesions in the
common and external carotid arteries or advanced ICA
lesions involving the ocular artery as a way of collateral
blood supply.17 Here, on investigating genes selected with
an a priori hypothesis gained through literature search,
gene-expression levels in plaques from patients with AF did
not differ significantly from plaques from patients with
either MS or TIA. Nevertheless, an overall evaluation of
gene-expression profiles suggests a dominant expression of
genes related to plaque stabilisation in plaques from
patients with AF, which may support the theory that AF
involves more discrete changes in plaque biology.
Making the assumption that the natural course of plaque
instability in patients with symptomatic carotid stenosis,
where the risk of stroke gradually subsides over time,
represents a time-dependent change in plaque phenotype,
we evaluated gene-expression profiles in relationship to the
time between the last symptom and surgery.5,7 Few genes
with a significant difference in expression were found in
plaques removed within 2 weeks, compared with those
removed between 1 and 3 months after a qualifying
symptom. Nevertheless, functional classification of genes
(Table 6, Supplement 3) suggests that lesions removed early
after symptoms of plaque instability are characterised by
less inflammation and proteolysis. In addition, various SMC-
marker genes were increased in lesions with short symptom-
free interval, while levels of macrophage and T-cell-marker
genes were lower. These findings suggest that plaque
rupture induces a rapid healing reaction, with activation of
SMCs that may lead to plaque stabilisation over time. We
also observed that gene-expression levels were either
increasing (e.g., TNF alpha) or decreasing (e.g., myocardin)
with time but returned to levels near the levels at the time
point when symptoms occurred (Fig. 1). Notably, a selection
bias influenced these findings, as patients with relatively
large infarctions, possibly caused by prominent plaque
rupture and more massive thrombosis, may be subjected to
delayed intervention and therefore prevail in the group of
patients operated later than 2 weeks after stroke.4
Our observations are contradictory to a number of
morphological studies, which have shown an abundance of
macrophages and increased proteolysis in lesions obtained
in the early phase after embolic symptoms.7,18 To our
knowledge, the present study is the first to analyse lesions
obtained within 14 days after an event as a separate group,
which may be an explanation for the different findings in
our study. It is important to note that the very first 2 weeksare responsible for most of the risk burden, as shown in
a number of studies.5,6 Of note, these investigations used
histomorphology, while we assessed gene-expression levels.
With respect to proteolysis, decreased macrophage infil-
tration with time from ischaemic event has been reported
without change in MMP-2, -8 and -9 activity, suggesting that
MMPs are produced by SMCs at later time points.18 By
contrast, we found an inverse correlation between
expression of SMC-marker genes and expression of MMP-7,
-9 and -12, suggesting inflammation-dependent MMP
expression.
The use of statins has been shown to decrease risk of
cerebral ischaemic events in a number of clinical trials, and
preoperative statin treatment has been demonstrated to
decrease macrophage infiltration and reduce MMP-9 in
carotid lesions.19 We observed that patients on statins had
increased expression of a large number of genes, such as von
Willebrand factor and elastin, while a few were suppressed
and no clear effect on the expression of either SMC-marker
genes or proteases was seen. These findings imply that sta-
tinsmay influenceplaquestabilitybypromotingexpressionof
extracellular-matrix genes in addition to their anti-
inflammatory features.10 In support of our interpretation
that statin treatment directly influences gene expression in
the atheroma, expression of geranylgeranylpyrophosphate
synthase was increased in plaques from statin-treated
patients, suggesting a compensatory response to inhibition
of HMG-CoA reductase.
Several morphological features of an atherosclerotic pla-
que can be visualised using ultrasound.20 Some of these
features, such as size of the necrotic core, degree of neo-
angiogenesis and fibrous-cap thickness, are related to an
inflammatory vulnerable phenotype of a lesion.4 In addition,
patientswithecholucentplaqueshavepreviouslybeenshown
to carry an increased risk of stroke.21 In the present study, we
correlated qualitative, routine, preoperative duplex
description of plaque echodensity with gene-expression
profile. In support of the previously reported association of
echodensity with plaque stability,9 we observed that echo-
lucent plaques had higher expression of genes related to
inflammation and proteolysis, while increased expression of
SMC-specific genes and genes for extracellular-matrix
proteins was observed in echodense lesions.
Among the 317 selected genes analysed, the expression
of several genes appeared to be more influenced by the
clinical variables than others (Table 3). Expression of MMPs
7, 9 and 12 and the macrophage marker CD68 corre-
lated to clinical variables indicating plaque instability,
whereas expression of elastin, myocardin and myosin heavy
chain were more frequently found to correlate to clinical
estimates of stable lesions. The data confirm that a balance
between synthesis of extracellular matrix by SMCs and
degradation by inflammatory cells lies behind clinical
manifestations of carotid atherosclerosis and should be
seen as a target for therapeutic strategies.Study limitations
A large number of samples are required to use human tissue
formicroarray analysis andmore than 100 samples have been
estimated to be necessary to overcome the heterogeneity of
Supplementary Material
The supplementary data associated with this article can be
found in the on-line version at doi:10.1016/j.ejvs.2011.05.
023.
Gene Expression in Carotid Atherosclerosis 729human populations.22 The present study included over 100
patients, which is still on the borderline, as subgroups
sometimes consisted of not more than 15 samples. This is
a likely explanation for the limited statistical significance in
many of our analyses. Moreover, the correction for multiple
tests would be required when a large number of comparisons
areperformed. In our study,wedecided to focus on thegenes
which showedmost of the change inmRNA levels.We believe
that such an approach may be more sensitive for the
processes of high biological significance than the current
strategies that rely on P value only. On the other hand, we
selected a number of genes with similar functions, which
gave us the possibility to evaluate expression trends in
relationship to clinical variables.
The use of expression data of single genes obtained from
microarrays may be controversial in the absence of vali-
dation through other methods, such as real-time poly-
merase chain reaction (RT-PCR) or immunohistochemistry.
This is partly because of the large number of genes ana-
lysed and also because of the original aim to explore if gene
expression in carotid atherosclerosis, as analysed with
microarrays, is influenced by clinical variables. In addition,
we have previously found adequate correlations between
microarray data and RT-PCR, when analysing expression of
individual genes in the BiKE database.11,23,24 A number of
other studies confirm that mRNA expression of matrix
proteinases correlates well with protein levels and more-
over with their enzymatic activity.25 In other publications,
it has been shown that, in human atherosclerotic lesions,
MMPs are mainly expressed by macrophages in the shoulder
region of the plaque.26 Therefore, we can rely on the
background data together with our data on cell-marker
expression and speculate on the presence of SMC and
macrophages in the lesions without histological validation.
Concerning the comparison of the gene expression between
carotid tissue and iliac samples, the two arteries may
differ, as they have different embryonic origins.Conclusions
Here, expression of a limited number of genes previously
described to be involved in plaque stability was analysed
with respect to clinical variables assumed to reflect lesion
phenotype. This validation may be considered a necessary
phase in the development and exploration of a gene-
expression database of human atherosclerotic lesions. We
evaluated the hypothesis that symptoms, statin treatment
and ultrasound morphology were clinical markers of plaque
stability, while time between the last qualifying symptom
and surgery would characterise patterns of plaque healing.
The described biobank platform will now be used to explore
new, unknown mediators and pathways of carotid plaque
instability and healing.Acknowledgements
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